ADMA Biologics (NASDAQ:ADMA) Rating Increased to Moderate Buy at Raymond James Financial

ADMA Biologics (NASDAQ:ADMA) was upgraded by research analysts at Raymond James Financial to a “moderate buy” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other research firms also recently issued reports on ADMA. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Mizuho decreased their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Canaccord Genuity Group reduced their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $19.67.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $8.48 on Wednesday. The firm has a 50-day moving average of $9.21 and a 200-day moving average of $14.26. The company has a market cap of $1.97 billion, a P/E ratio of 12.47 and a beta of 0.72. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. ADMA Biologics has a one year low of $7.21 and a one year high of $22.37.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. The company had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.11 earnings per share. Equities research analysts forecast that ADMA Biologics will post 0.84 EPS for the current fiscal year.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman bought 12,500 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds have recently bought and sold shares of the stock. Western Wealth Management LLC purchased a new position in shares of ADMA Biologics during the first quarter worth approximately $31,000. Bank of America Corp DE raised its stake in shares of ADMA Biologics by 107.5% during the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock worth $36,019,000 after acquiring an additional 2,071,338 shares in the last quarter. Amundi raised its stake in shares of ADMA Biologics by 62.9% during the first quarter. Amundi now owns 51,761 shares of the biotechnology company’s stock worth $466,000 after acquiring an additional 19,985 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of ADMA Biologics by 24.0% during the first quarter. California State Teachers Retirement System now owns 279,124 shares of the biotechnology company’s stock worth $2,515,000 after acquiring an additional 53,988 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of ADMA Biologics by 448.8% during the first quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock worth $8,373,000 after acquiring an additional 759,984 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.